Cyclic Urea Thiazolyl Antiviral for Drug-Resistant HSV
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral therapies for herpes simplex virus (HSV) infections, such as nucleoside analogues and helicase-primase inhibitors, are inadequate in treating resistant strains and have safety concerns, leading to recurrent outbreaks and transmission risks.
Innovation Solution
A novel cyclic urea thiazolyl compound (Compound 1) is administered to treat HSV infections unresponsive to first antiviral therapies, offering enhanced potency and safety, with potential synergistic effects when combined with existing treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleoside analogues are used to treat HSV infections, then viral replication is inhibited, but resistant strains develop and recurrent outbreaks occur
Solution Approach 1:
The patent changes the chemical structure and mechanism of action parameters by using a cyclic urea thiazolyl compound that inhibits the viral primase enzyme directly, rather than relying on thymidine kinase phosphorylation like nucleoside analogues. This fundamental parameter change in mechanism allows the compound to remain effective against resistant strains that have mutated their TK or primase enzymes.
Solution Approach 2:
The patent extracts the dependency on thymidine kinase phosphorylation from the antiviral mechanism. By using a direct primase inhibitor that does not require TK activation, the compound eliminates the vulnerability to TK-negative mutants and resistant strains that have evolved to bypass nucleoside analogue activation pathways.
2Reliability
If high doses of nucleoside analogues are administered, then viral replication is more effectively inhibited, but adverse effects increase
Solution Approach 1:
The patent changes the dose-response parameter relationship by using a compound with direct primase inhibition mechanism that achieves effective viral suppression at lower doses. The cyclic urea thiazolyl compound's direct action on primase eliminates the need for high-dose nucleoside analogue therapy, thereby reducing adverse effects while maintaining viral suppression efficacy.
3Duration of action of stationary object
If long-term suppressive treatment with nucleoside analogues is used, then recurrent outbreaks are reduced, but transmission risk decreases only partially
Solution Approach 1:
The patent changes the therapeutic outcome parameter by using a primase inhibitor that achieves more effective and durable viral suppression. The cyclic urea thiazolyl compound's mechanism directly targeting primase results in more reliable transmission prevention compared to nucleoside analogues, while maintaining long-term suppressive treatment efficacy.
4Reliability
If nucleoside analogues are used to treat HSV, then viral replication is inhibited, but mutagenicity concerns arise
Solution Approach 1:
The patent extracts the mutagenic risk associated with nucleoside analogue incorporation into host DNA. By using a direct primase inhibition mechanism, the compound eliminates the pathway where nucleoside analogues can be incorporated into host genomes via host DNA polymerase, thereby removing the mutagenicity concern while maintaining antiviral activity.
Data Source
AI summary
The present disclosure provides methods and pharmaceutical formulations for the treatment and prophylaxis of a viral infection unresponsive to treatment with one or more first antiviral therapy using a cyclic urea thiozole compound.